The Peptide NewsroomPeptide research, industry and supply-chain headlines

FDA Sends Five Warning Letters to Peptide Sellers Over Unapproved Weight-Loss Copies

By The Peptide Newsroom Desk · Date: 0views 0comments
Topic card: fda

The US Food and Drug Administration has issued five warning letters to online peptide sellers, according to a report by Pharmaceutical Technology, all of them centered on unapproved weight-loss and fat-reducing compounds. The named companies are Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners and TXP Innovations LLC dba Tex Peptides.

The letters detail violations of FDA regulations covering the sale of new peptide-based drugs that remain unapproved and unregulated. All five sites were flagged for advertising their own versions of retatrutide, Eli Lilly's obesity candidate, which has not secured approval in any global market.

The retatrutide problem

Retatrutide is the clearest case here because there is no legitimate consumer version of it anywhere on earth. Lilly itself sounded the alarm on the drug's growing black market shortly before this, as some patients look for cheaper alternatives to branded weight-loss medicines.

All five companies are also offering illegal variations of semaglutide, Novo Nordisk's GLP-1 receptor agonist sold in the US as Wegovy for obesity and Ozempic for type 2 diabetes. That is the pattern regulators keep finding: the compound with the biggest waiting list attracts the biggest gray market.

Not just weight loss

The rosters go well beyond obesity drugs, into growth hormone release-stimulating, muscle-boosting and libido-enhancing products. Pharmaceutical Technology lists copycat versions of Theratechnologies' abdominal fat-reducing Egrifta (tesamorelin), Mighty Therapeutics' Barth syndrome drug Forzinity (elamipretide) and Cosette Pharmaceuticals' Vyleesi (bremelanotide) for hypoactive sexual desire disorder.

The research-use-only defense

Every site reviewed sells these peptides under a research-only label, stating they are "not for veterinary or human use." The FDA refutes that, saying evidence from each website establishes the products are intended for human use.

The letters also flag the dangers of unregulated injectables, which the agency says "can pose risks of serious harm to users" because they enter the bloodstream directly and bypass the body's natural defenses against toxins and pathogens. That is the part of this story with actual stakes, and it is independent of whether any given molecule works.

Two directions at once

The timing is odd. While the FDA sends warning letters, its advisory board recently voted to relax peptide restrictions, potentially allowing specialized pharmacies to supply multiple peptides without full clinical testing.

Karsten Eastman, CEO of regulated peptide developer Sethera, told Pharmaceutical Technology there is a dire need for greater public clarity around peptides and their potential. On current evidence, he is not wrong.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: fda

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Tirzepatide Research Digest: What SURPASS-CVOT Measured, and What It Left Open

The FDA approved Mounjaro for cardiovascular risk reduction on the strength of SURPASS-CVOT, a trial of more than 13,000 participants that compared it head-to-head with Trulicity. Here is what that trial measured, what clinicians said about the mechanism, and the questions the researchers say remain open.

FDA Approves Mounjaro for Cardiovascular Risk Reduction, But the Trial Population Was Narrow

The FDA has approved Mounjaro to reduce cardiovascular risk in high-risk people with type 2 diabetes, based on a 13,000-person head-to-head trial against Trulicity. Major cardiovascular events occurred in 12.2% of Mounjaro participants versus 13.1% on the comparator, and cardiologists caution the studied population was unusually high risk.

Bengaluru 'Peptide Party' Cancelled After Karnataka FDA Demands Answers on Products and Claims

The Karnataka FDA says a "Peptide Party" planned for Koramangala on August 29 was cancelled after the department demanded composition, dosage, manufacturer and regulatory-status details from organizers Upsurge Labs LLP. The notice also sought scientific evidence for claims spanning weight loss, muscle growth, anti-aging, diabetes and athletic performance.